

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
09 September 2022 (09.09.2022)



(10) International Publication Number

WO 2022/186871 A1

(51) International Patent Classification:

A61K 31/00 (2006.01) B82Y 5/00 (2011.01)

A61P 25/28 (2006.01)

(21) International Application Number:

PCT/US2021/062908

(22) International Filing Date:

10 December 2021 (10.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/154,899 01 March 2021 (01.03.2021) US

(71) Applicant: PHARMZANDIA CORPORATION

[US/US]; 1000 N Green Valley Pkwy. #440-339, Henderson, Nevada 89074 (US).

(72) Inventor: BUTZLOFF, Peter; c/o Rimon, PC, 800 Oak

Grove Avenue, Suite 250, Menlo Park, California 94025 (US).

(74) Agent: HAYDEN, Robert et al.; Rimon PC, 800 Oak

Grove Avenue, #250, Menlo Park, California 94025 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: C60 GLUTATHIONE DOPA AND METHODS




FIG. 6

(57) Abstract: A novel dual neurotransmitter nanoparticle composition is provided to store and transport protons and cations into neural cell membranes and to disassemble salt-bridge stabilized toxic protein plaques. These properties function to mitigate cognitive deficits in neurological diseases such as Parkinsons disease and Alzheimers disease, as well as to reduce the severity of aging related reactive oxygen species damage by the sequestration and termination of free radicals and reactive oxygen species. The composition comprises C60 bonded to one or more glutathione molecules and one or more molecules of either levodopa or dopamine. The composition can be produced at low temperatures through reactive shear milling. This composition therapeutically improves and prophylactically preserves cognitive performance, memory, and mental acuity on aging to promote mental performance and health-span improvement